Scope All Day Cpc Antigingivitis/antiplaque Mouthwash All Day
Cetylpyridinium Chloride
The Procter & Gamble Manufacturing Company
Human Otc Drug
NDC 69423-856Scope All Day Cpc Antigingivitis/antiplaque Mouthwash All Day also known as Cetylpyridinium Chloride is a human otc drug labeled by 'The Procter & Gamble Manufacturing Company'. National Drug Code (NDC) number for Scope All Day Cpc Antigingivitis/antiplaque Mouthwash All Day is 69423-856. This drug is available in dosage form of Rinse. The names of the active, medicinal ingredients in Scope All Day Cpc Antigingivitis/antiplaque Mouthwash All Day drug includes Cetylpyridinium Chloride - .07 g/mL . The currest status of Scope All Day Cpc Antigingivitis/antiplaque Mouthwash All Day drug is Active.
Drug Information:
| Drug NDC: | 69423-856 |
| The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC. |
| Proprietary Name: | Scope All Day Cpc Antigingivitis/antiplaque Mouthwash All Day |
| Also known as the trade name. It is the name of the product chosen by the labeler. |
| Proprietary Name Base: | Scope All Day Cpc Antigingivitis/antiplaque Mouthwash |
| The base of the Brand/Proprietary name excluding its suffix. |
| Proprietary Name Suffix: | All Day |
| A suffix to the proprietary name, a value here should be appended to the ProprietaryName field to obtain the complete name of the product. This suffix is often used to distinguish characteristics of a product such as extended release (“XR”) or sleep aid (“PM”). Although many companies follow certain naming conventions for suffices, there is no recognized standard. |
| Product Type: | Human Otc Drug |
| Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing. |
| Non Proprietary Name: | Cetylpyridinium Chloride |
| Also known as the generic name, this is usually the active ingredient(s) of the product. |
| Labeler Name: | The Procter & Gamble Manufacturing Company |
| Name of Company corresponding to the labeler code segment of the ProductNDC. |
| Dosage Form: | Rinse |
| The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources. |
| Status: | Active |
| FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved. |
| Substance Name: | CETYLPYRIDINIUM CHLORIDE - .07 g/mL
|
| This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted. |
| Route Details: | ORAL
|
| The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. |
Marketing Information:
An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
| Marketing Category: | OTC MONOGRAPH NOT FINAL |
| Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. |
| Marketing Start Date: | 01 Jan, 2022 |
| This is the date that the labeler indicates was the start of its marketing of the drug product. |
| Marketing End Date: | 25 Dec, 2025 |
| This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached. |
| Application Number: | part356 |
| This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null. |
| Listing Expiration Date: | 31 Dec, 2023 |
| This is the date when the listing record will expire if not updated or certified by the firm. |
OpenFDA Information:
An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
| Manufacturer Name: | The Procter & Gamble Manufacturing Company
|
| Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC. |
| Original Packager: | Yes
|
| Whether or not the drug has been repackaged for distribution. |
| UNII: | D9OM4SK49P
|
| Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information. |
Packaging Information:
| Package NDC | Description | Marketing Start Date | Marketing End Date | Sample Available |
|---|
| 69423-856-33 | 1000 mL in 1 BOTTLE, PLASTIC (69423-856-33) | 01 Jan, 2022 | N/A | No |
| Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together. |
Purpose:
Purpose antigingivitis/antiplaque
Product Elements:
Scope all day cpc antigingivitis/antiplaque mouthwash all day cetylpyridinium chloride saccharin sodium water glycerin methylparaben propylparaben poloxamer 407 sucralose zinc lactate cetylpyridinium chloride cetylpyridinium
Indications and Usage:
Uses helps prevent and reduce plaque and gingivitis helps control plaque bacteria that contribute to the development of gingivitis and bleeding gums
Warnings:
Warning ask a dentist if symptoms persist or condition worsens after regular use. keep out of reach of children 6 years of age. if more than used for rinsing is accidentally swallowed, get medical help or contact a poison control center right away.
Ask a dentist if symptoms persist or condition worsens after regular use.
Dosage and Administration:
Directions use after your normal brushing and flossing routine, rinse toothpaste from mouth prior to use adults and children 6 yrs. & older: rinse for 30 seconds with 20 ml (4 teaspoonfuls) twice a day do not swallow children 6 years to under 12 years of age: supervise use children under 6 years of age: do not use
Package Label Principal Display Panel:
Principal display panel 1l bottle clean mint all fresh no stress⢠scope® cpc antigingivitis/antiplaque mouthwash all day plus 24 hr breath protection* kills 99% of bad breath bacteria mild flavor alcohol free 1 l (33.8 fl oz) scope all day cpc mouthwash
Further Questions:
Questions? 1-800-285-9139